Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease

References

• Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann. NY Acad. Sci.991, 1–14 (2003).
   PubMed Web of Science ®Google Scholar
• von Campenhausen S, Bornschein B, Wick R et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur. Neuropsychopharmacol.15(4), 473–490 (2005).
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord.16(3), 448–458 (2001).
   PubMed Web of Science ®Google Scholar
• Muller T, Erdmann C, Bremen D et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin. Neuropharmacol.29(2), 61–67 (2006).
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lennernas H, Gomes-Trolin C, Aquilonius SM. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson’s disease on individual drug combinations. Clin. Neuropharmacol.25(2), 89–96 (2002).
   PubMed Web of Science ®Google Scholar
• Chase TN. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat. Disord.10(5), 305–313 (2004).
   PubMed Web of Science ®Google Scholar
• Widnell K. Pathophysiology of motor fluctuations in Parkinson’s disease. Mov. Disord.20(Suppl. 11), S17–S22 (2005).
   PubMedGoogle Scholar
• Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson’s disease: state of the art in 2004. Clin. Neuropharmacol.27(5), 245–256 (2004).
   PubMed Web of Science ®Google Scholar
• Pahwa R, Factor SA, Lyons KE et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66(7), 983–995 (2006).
   PubMed Web of Science ®Google Scholar
• Movement Disorder Society Task Force. Management of Parkinson’s disease: an evidence-based review. Mov. Disord.17(Suppl. 4), S1–S166 (2002).
   PubMedGoogle Scholar
• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology56(11 Suppl. 5), S1–S88 (2001).
   PubMed Web of Science ®Google Scholar
• Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin. Pharmacokinet.45(2), 109–136 (2006).
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinson’s disease. Expert Rev. Neurother.6(1), 81–89 (2006).
   PubMedGoogle Scholar
• Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov. Disord.19(9), 997–1005 (2004).
   PubMed Web of Science ®Google Scholar
• Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J. Neurol.252(Suppl. 4), IV37–IV42 (2005).
   PubMed Web of Science ®Google Scholar
• Lees AJ. Drugs for Parkinson’s disease. J. Neurol. Psychiatr.73(6), 607–610 (2002).
   PubMed Web of Science ®Google Scholar
• Kurlan R. “Levodopa phobia”: a new iatrogenic cause of disability in Parkinson disease. Neurology64(5), 923–924 (2005).
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Nyholm D. New developments in levodopa therapy. Neurology62(1 Suppl. 1), S9–S16 (2004).
   PubMed Web of Science ®Google Scholar
• Baas H, Zehrden F, Selzer R, Kohnen R, Loetsch J, Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson’s disease. Clin. Pharmacokinet.40(5), 383–393 (2001).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol.62(6), 905–910 (2005).
   PubMed Web of Science ®Google Scholar
• Koller W, Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology62(6 Suppl. 4), S22–S26 (2004).
   PubMed Web of Science ®Google Scholar
• Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov. Disord.17(6), 1235–1241 (2002).
   PubMed Web of Science ®Google Scholar
• Guldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin. Neuropharmacol.28(3), 106–110 (2005).
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lewander T, Johansson A, LeWitt P, Lundqvist C, Aquilonius S. Intraduodenal infusion of a gel suspension of levodopa/carbidopa, Duodopa®, in advanced Parkinson’s disease: safety, tolerability, efficacy and dosage. Mov. Disord.19(Suppl. 9), S177 (2004).
   Google Scholar
• Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by [11C]raclopride displacement and PET. Neurology46(5), 1430–1436 (1996).
   PubMed Web of Science ®Google Scholar
• Sjalander-Brynne L, Paalzow LK. Pharmacodynamic aspects of drug administration. Tolerance development. Adv. Drug Deliv. Rev.33(3), 235–240 (1998).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Bonamartini A, Vacca L, Ruggieri S. Motor fluctuations in levodopa treatment: clinical pharmacology. Eur. Neurol.36(Suppl. 1), 38–42 (1996).
   PubMed Web of Science ®Google Scholar
• Nyholm D, Askmark H, Gomes-Trolin C et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin. Neuropharmacol.26(3), 156–163 (2003).
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol.2(2), 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton RL, Committee UPDRS. Unified Parkinson’s disease rating scale. In: Recent Developments in Parkinson’s Disease. Fahn S, Marsden CD, Calne DB, Goldstein M (Eds). Macmillan Healthcare Information, NJ, USA, 153–163 (1987).
   Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology64(2), 216–223 (2005).
   PubMed Web of Science ®Google Scholar
• Lewander T, Sydow O, Wedlund J, Maehle-Schmidt M, Pålhagen S, Nyholm D. Videoscoring: a computerized method for blinded assessment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Mov. Disord.19(Suppl. 9), S256 (2004).
   Google Scholar
• Bredberg E, Nilsson D, Johansson K et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson’sParkinson’s disease. Eur. J. Clin. Pharmacol.45(2), 117–122 (1993).
   PubMed Web of Science ®Google Scholar
• Nilsson D, Hansson LE, Johansson K, Nystrom C, Paalzow L, Aquilonius SM. Long-term intraduodenal infusion of a water based levodopa–carbidopa dispersion in very advanced Parkinson’s disease. Acta Neuro. Scand.97(3), 175–183 (1998).
   PubMed Web of Science ®Google Scholar
• Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease-long-term experience. Acta Neurol. Scand.104(6), 343–348 (2001).
   PubMed Web of Science ®Google Scholar
• Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann. Med.33(5), 328–336 (2001).
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing26(5), 353–357 (1997).
   PubMed Web of Science ®Google Scholar
• Isacson D, Bingefors K, Nyholm D, Kristiansen IS. Effect of continuous duodenal infusion of levodopa (Duodopa®) on self-reported symptoms in patients with severe Parkinson’s disease: a follow-up. Parkinsonism Relat. Disord.11(Suppl. 2), S216–S217 (2005).
   Google Scholar
• Westin J, Nyholm D, Groth T, Dougherty MS, Yerramsetty PK, Palhagen SE. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson’s disease. Parkinsonism Relat. Disord.(2006) (E-pub ahead of print).
   PubMed Web of Science ®Google Scholar
• Nyholm D, Jansson R, Willows T, Remahl IN. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology65(9), 1506–1507 (2005).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Deleu D, Hanssens Y et al. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology66(10), 1611–1612 (2006).
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology40(6), 995–997 (1990).
   PubMed Web of Science ®Google Scholar
• Kristiansen IS, Bingefors C, Nyholm D, Isacson D. The cost–effectiveness of continuous duodenal delivery of levodopa (Duodopa®) in patients with severe Parkinson’s disease. Mov. Disord.20(Suppl. 10), S80 (2005).
   Google Scholar
• Nyholm D, Aquilonius SM. Intestinal infusion of Duodopa® – eight years’ experience. Parkinsonism Relat. Disord.7(Suppl.), S64 (2001).
   Google Scholar
• Syed N, Murphy J, Zimmerman T Jr, Mark MH, Sage JI. Ten years’ experience with enteral levodopa infusions for motor fluctuations in Parkinson’s disease. Mov. Disord.13(2), 336–338 (1998).
   PubMed Web of Science ®Google Scholar
• Khokhar N, Gill ML. Percutaneous endoscopic gastrostomy: nine years experience in a tertiary care centre in Pakistan. J. Pak Med Assoc.55(3), 108–110 (2005).
   PubMedGoogle Scholar
• Guehl D, Tison F, Cuny E et al. Complications and adverse effects of deep brain stimulation in Parkinson’s patients. Expert Rev. Neurother.3(6), 811–819 (2003).
   PubMedGoogle Scholar
• Umemura A, Jaggi JL, Hurtig HI et al. Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J. Neurosurg.98(4), 779–784 (2003).
   PubMed Web of Science ®Google Scholar
• Lundqvist C, Nystedt T, Reiertsen O, Grotli R, Beiske AG. Continuous treatment with levodopa of Parkinson disease. Tidsskr. Nor. Laegeforen.125(19), 2638–2640 (2005).
   PubMedGoogle Scholar
• Karlsborg M, Regeur L. New types of dopaminergic treatment. The Danish Society of Movement Disorders. Ugeskr. Laeg.168(12), 1209 (2006).
   PubMedGoogle Scholar